PRA Completes 20th First in Human Biologics Trial
PRA announced it has completed its 20th first in human trial with biologics.
PRA announced it has completed its 20th first in human trial with biologics. The milestone is the culmination of 600 subjects enrolled in over eight years of first in human biologics trials, including directly into patient experience. Biologics represent an important class of agents with an increasing share in modern medicine, as a response to improved understanding of molecular and genetic bases of disease.
Read the full release here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ponsegromab Significantly Improves Body Weight in Patients with Cancer Cachexia
September 17th 2024Results of a Phase II study of ponsegromab showed significant improvements in body weight, muscle function, and overall symptoms for patients with cancer cachexia, offering hope for a new targeted treatment.
Imfinzi Plus Imjudo Shows Significant Five-Year Survival Improvement in Unresectable Liver Cancer
September 16th 2024Data from the Phase III HIMALAYA trial found the combination of Imfinzi plus Imjudo reduced the risk of death by 24% compared to sorafenib in patients with unresectable hepatocellular carcinoma.
